The 2026 Peptide Regulatory Timeline: Cat-2 Removals, the PCAC Votes, and What Comes Next

One year of US peptide regulation moved faster than the previous decade. This is the tracker — dates, tallies, and what each step did and didn’t decide.

Background: how we got here

Section 503A of the FD&C Act lets pharmacies compound from bulk substances on (or eligible for) the Bulks List. In 2023 the FDA found the nomination files for ~19 popular peptides — BPC-157, TB-500, CJC-1295 and others — legally insufficient, which functionally froze compounding. The June 2025 categorical framework then sorted nominees into Category 1 (proceed with evaluation), Category 2 (significant safety risks — compounding effectively prohibited) and Category 3 (insufficient data). Most research-peptide headlines since then are about movement between these buckets.

2026, month by month

Date	Event	Peptides
Apr 2026	FDA removes 12 substances from the 503A Category 2 list pending PCAC evaluation	BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, Selank, DSIP, GHK-Cu, Melanotan II, Dihexa, Ipamorelin (specific salt forms)
Jul 23-24, 2026	PCAC meets at White Oak; seven substances reviewed	see tallies below
Aug-Sep 2026	No final rule; recommendations pending at FDA	—
Feb 2027 (scheduled)	Next PCAC cycle for remaining April cohort	GHK-Cu, Melanotan II and others

The July tallies, exactly

• BPC-157 — 8 : 6, one abstention (overruling the staff’s negative preliminary assessment)
• KPV — 8 : 6; TB-500 — 8 : 6
• MOTS-c — 7 : 5; Epitalon — 7 : 4, one abstention; Semax — majority in favor
• Emideltide — rejected (the only no)

Our meeting-level analysis with safety-signals context: FDA Panel Backs Six Peptides.

What each step decides — and doesn’t

Cat-2 removal deletes the “significant safety risk” flag; it grants nothing. PCAC yes-votes are advisory recommendations toward Bulks Listing — the FDA is free to follow, modify or ignore them, and final listing needs notice-and-comment rulemaking. Between the two sits the honest status for the July six: recommended, not resolved.

Buying posture while the ink dries

Three practical reads for research supply: (1) documentation quality will matter more, not less — rulemaking will audit the batch-paper trail (see how to read a COA); (2) vendors making “FDA compliant” claims about these peptides today are describing a process that hasn’t concluded — ask which specific step they mean (supplier checks); (3) catalog continuity is a real risk factor: the six recommended compounds are the safest long-term catalog bets in the peptide space right now, and the February 2027 queue is the next date to watch.

References: FDA, “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee” (advisory-committee calendar, fda.gov) · AJMC, “FDA Panel Backs 6 Peptides for Compounding,” July 2026 · FDA, “Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks” (Category 2 page, updated May 14, 2026).

For laboratory research use only. Not medical or legal advice. Statuses summarized September 2026.